Bortezomib (Btz) dose intensity is the strongest predictor for overall survival (OS) in mantle cell lymphoma (MCL) patients (Pts) not considered for transplantation, receiving frontline Btz plus rituximab, cyclosphosphamide, doxorubicin, and prednisone (VR-CAP) therapy in the phase 3 LYM 3002 study (2014)
- Authors:
- Autor USP: PEREIRA, JULIANA - FM
- Unidade: FM
- Subjects: LINFOMA (TERAPIA); FÁRMACOS DO SANGUE E SISTEMA HEMATOPOÉTICO; SOBREVIDA
- Language: Inglês
- Imprenta:
- Source:
- Título: Blood
- Volume/Número/Paginação/Ano: v. 124, n. 21, res. 4412, suppl, 2014
- Conference titles: Annual Meeting and Exposition / ASH
-
ABNT
ROBAK, Tadeusz et al. Bortezomib (Btz) dose intensity is the strongest predictor for overall survival (OS) in mantle cell lymphoma (MCL) patients (Pts) not considered for transplantation, receiving frontline Btz plus rituximab, cyclosphosphamide, doxorubicin, and prednisone (VR-CAP) therapy in the phase 3 LYM 3002 study. Blood. New York: Faculdade de Medicina, Universidade de São Paulo. Disponível em: http://www.hematology.org/Annual-Meeting/Program/Education-Program.aspx. Acesso em: 23 fev. 2026. , 2014 -
APA
Robak, T., Huang, H., Jim, J., Shu, J., Liu, T., Samailova, O. S., et al. (2014). Bortezomib (Btz) dose intensity is the strongest predictor for overall survival (OS) in mantle cell lymphoma (MCL) patients (Pts) not considered for transplantation, receiving frontline Btz plus rituximab, cyclosphosphamide, doxorubicin, and prednisone (VR-CAP) therapy in the phase 3 LYM 3002 study. Blood. New York: Faculdade de Medicina, Universidade de São Paulo. Recuperado de http://www.hematology.org/Annual-Meeting/Program/Education-Program.aspx -
NLM
Robak T, Huang H, Jim J, Shu J, Liu T, Samailova OS, Pereira J, Pylypenko H, Verhoef G, Siritanaratkul N, Osmanov EA, Alexeeva J, Mayer J, Hong X, Maeda Y, Rooney B, van de Velde H, Cavalli F. Bortezomib (Btz) dose intensity is the strongest predictor for overall survival (OS) in mantle cell lymphoma (MCL) patients (Pts) not considered for transplantation, receiving frontline Btz plus rituximab, cyclosphosphamide, doxorubicin, and prednisone (VR-CAP) therapy in the phase 3 LYM 3002 study [Internet]. Blood. 2014 ; 124( 21):[citado 2026 fev. 23 ] Available from: http://www.hematology.org/Annual-Meeting/Program/Education-Program.aspx -
Vancouver
Robak T, Huang H, Jim J, Shu J, Liu T, Samailova OS, Pereira J, Pylypenko H, Verhoef G, Siritanaratkul N, Osmanov EA, Alexeeva J, Mayer J, Hong X, Maeda Y, Rooney B, van de Velde H, Cavalli F. Bortezomib (Btz) dose intensity is the strongest predictor for overall survival (OS) in mantle cell lymphoma (MCL) patients (Pts) not considered for transplantation, receiving frontline Btz plus rituximab, cyclosphosphamide, doxorubicin, and prednisone (VR-CAP) therapy in the phase 3 LYM 3002 study [Internet]. Blood. 2014 ; 124( 21):[citado 2026 fev. 23 ] Available from: http://www.hematology.org/Annual-Meeting/Program/Education-Program.aspx - Adult T-Cell Leukemia/Lymphoma: A Clinical and Epidemiological Analysis at the Medicine School of Sao Paulo University
- How to manage lymphoid malignancies during novel 2019 coronavirus (CoVid-19) outbreak: a Brazilian task force recommendation
- Radiographic patterns of multiple myeloma in the jawbones of patients treated with intravenous bisphosphonates
- GATA-3 is a proto-oncogene in T-cell lymphoproliferative neoplasms
- Comparison of Subcutaneous Versus Intravenous Administration of Rituximab As Maintenance Treatment for Follicular Lymphoma: Results From a Two-Stage, Phase IB Study
- Panoramic and skull imaging may aid in the identification of multiple myeloma lesions
- Estudo de células precuroras em leucemias agudas: identificação e fator de prognóstico das proteínas Bcl-2, Bax e CD95/Fas/APO-1
- Targeted therapy with nanatinostat and valganciclovir in recurrent EBV-positive lymphoid malignancies: a phase 1b/2 study
- 18 F-FDG pet interim and determination of cellular origin by immunohistochemistry identify a group of very good prognosis in patients with diffuse large B cell lymphoma in the rituximab era
- Immune reconstitution inflammatory syndrome-associated lymphoma: a retrospective Brazilian cohort
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
